MacroGenics, Inc. (NASDAQ:MGNX) had its target price hoisted by Citigroup Inc. from $18.00 to $22.00 in a report issued on Friday morning. Citigroup Inc. currently has a neutral rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research raised MacroGenics from a sell rating to a hold rating and set a $19.00 price objective for the company in a research note on Tuesday, July 18th. Stifel Nicolaus reissued a buy rating and set a $34.00 price objective on shares of MacroGenics in a research note on Tuesday, September 12th. SunTrust Banks, Inc. reissued a buy rating and set a $26.00 price objective on shares of MacroGenics in a research note on Friday, September 1st. Cowen and Company reissued a buy rating on shares of MacroGenics in a research note on Wednesday, October 25th. Finally, ValuEngine raised MacroGenics from a strong sell rating to a sell rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. MacroGenics presently has an average rating of Buy and an average price target of $30.10.

MacroGenics (NASDAQ:MGNX) traded down $0.83 during trading on Friday, hitting $17.85. The stock had a trading volume of 233,000 shares, compared to its average volume of 261,523. MacroGenics has a 52-week low of $14.36 and a 52-week high of $31.85.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $5.50 million. MacroGenics had a negative return on equity of 89.68% and a negative net margin of 2,828.80%. MacroGenics’s revenue was down 48.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.97) earnings per share. research analysts anticipate that MacroGenics will post -2.34 EPS for the current fiscal year.

WARNING: “Citigroup Inc. Boosts MacroGenics, Inc. (MGNX) Price Target to $22.00” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/citigroup-inc-boosts-macrogenics-inc-mgnx-price-target-to-22-00/1702795.html.

In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares in the company, valued at $800,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC raised its position in MacroGenics by 0.6% during the second quarter. Jennison Associates LLC now owns 189,970 shares of the biopharmaceutical company’s stock valued at $3,326,000 after purchasing an additional 1,062 shares in the last quarter. American International Group Inc. increased its holdings in shares of MacroGenics by 7.1% in the first quarter. American International Group Inc. now owns 19,632 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 1,300 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of MacroGenics by 21.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 148,792 shares of the biopharmaceutical company’s stock worth $2,606,000 after buying an additional 25,823 shares during the period. Vanguard Group Inc. increased its holdings in shares of MacroGenics by 3.4% in the first quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock worth $25,163,000 after buying an additional 44,680 shares during the period. Finally, FMR LLC increased its holdings in shares of MacroGenics by 6.0% in the second quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock worth $91,733,000 after buying an additional 295,553 shares during the period. Institutional investors and hedge funds own 84.72% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.